Reconstructive Treatment for Antiretroviral-Associated Facial Lipoatrophy: A Prospective Study Comparing Autologous Fat and Synthetic Substances
Eugènia Negredo(Universitat de Vic - Universitat Central de Catalunya), Bonaventura Clotet(Universitat de Vic - Universitat Central de Catalunya), Xavier Adell(Hospital Universitari Germans Trias i Pujol), Carmina R. Fumaz(Universitat Autònoma de Barcelona), Carmen Higueras(Hospital Universitari Germans Trias i Pujol), Jordi Puig(Universitat Autònoma de Barcelona), Denise Cinquegrana(Johns Hopkins University), José A. Muñoz-Moreno(University of California San Diego), Núria Pérez‐Álvarez(Universitat Autònoma de Barcelona), Carla Estany(Universitat Autònoma de Barcelona), Juan Carlos Martínez(Universitat Autònoma de Barcelona), Sebastián Videla(Universitat Autònoma de Barcelona), Eva Martínez(Universitat Autònoma de Barcelona), V. González-Mestre(Hospital Universitari Germans Trias i Pujol)
Cited by 57
Related Papers
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
Assessment, Diagnosis, and Treatment of HIV-Associated Neurocognitive Disorder: A Consensus Report of the Mind Exchange Program
|Clinical Infectious Diseases|2012|208
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
|The Lancet Infectious Diseases|2011|172
Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2005|151
Factors Associated With Missed Appointments at an Academic Pain Treatment Center: A Prospective Year-Long Longitudinal Study
|Anesthesia & Analgesia|2017|73